Owned by the Association for International Promotion & Study in Tumors (APSIT)
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical...